Antithrombotic and Prohemorrhagic Actions of Different Concentrations of Apixaban in Patients Exposed to Single and Dual Antiplatelet Regimens
Authors:
- Julia Martinez-SanchezJMJulia Martinez-Sanchez
- Leticia CastrilloLCLeticia Castrillo
- Didac JerezDJDidac Jerez
- Sergi Torramade-MoixSTSergi Torramade-Moix
- Marta PalomoMPMarta Palomo
- Guiomar MendietaGMGuiomar Mendieta
- Ana Belén Moreno-CastañoAMAna Belén Moreno-Castaño
- M. Urooj ZafarMZM. Urooj Zafar
- Juan Jose BadimonJuan Jose Badimon
- Maribel Diaz-RicartMDMaribel Diaz-Ricart
- Gines EscolarGEGines Escolar
- Mercè RoquéMRMercè Roqué
Preprint
- 9 December 2022
- preprint
- Published by Springer Nature in Research Square
Abstract
BACKGROUND: Treatment with triple antithrombotic therapies increases bleeding risks. AIM: We evaluated the antithrombotic and prohemorrhagic actions of different concentrations of apixaban (APIX) in healthy donors and patients exposed to currently used antiplatelet regimens. METHODS: 25 healthy subjects and 53 patients treated with aspirin (ASA, n=21), ASA and clopidogrel (ASA+CLOPI, n=11), or ASA and ticagrelor (ASA+TICA, n=21) participated in the study. Blood samples from participants were spiked ex vivo with apixaban 0 (APIX0), 40 (APIX40), and 160 ng/mL (APIX160). We assessed the effects of APIX on 1) clot formation, by ROTEM thromboelastometry; 2) thrombin generation primed by platelets; and 3) platelet and fibrin interactions with a thrombogenic surface, in a microfluidic model with circulating blood. RESULTS: APIX caused dose-related prolongations of clotting time with minimal impact on other ROTEM parameters. Thrombin generation was significantly inhibited by APIX160 and moderately affected by the antiplatelets, with ASA+TICA actions being the strongest among them (pCONCLUSIONS: APIX potentiated the antithrombotic effects of current antiplatelet regimens. APIX at 40 ng/mL, enhanced the antithrombotic action of single or dual antiplatelet regimens but appears more conservative for hemostasis than the concentrations of 160 ng/mL that corresponds to the Cmax reached after the standard dose for thromboprophylaxis.Keywords
All Related Versions
This publication has 28 references indexed in Scilit:
- Reversing direct factor Xa or thrombin inhibitors: Factor V addition to prothrombin complex concentrate is beneficial in vitroResearch and Practice in Thrombosis and Haemostasis, 2022
- Effect of anticoagulants on fibrin clot structure: A comparison between vitamin K antagonists and factor Xa inhibitorsResearch and Practice in Thrombosis and Haemostasis, 2020
- Rationale and design for the study Apixaban versus ClopidoGRel on a background of aspirin in patient undergoing InfraPoPliteal angioplasty for critical limb ischemia: AGRIPPA trialAmerican Heart Journal, 2020
- Thrombin generation induced by tissue factor plus ADP in human platelet rich plasma: A potential new measurement to assess the effect of the concomitant use of an oral factor Xa inhibitor edoxaban and P2Y12 receptor antagonistsThrombosis Research, 2015
- An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI)American Heart Journal, 2015
- Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and BleedingJACC, 2013
- Effects on platelet function of a direct acting antagonist of coagulation factor XaJournal of Thrombosis and Thrombolysis, 2012
- Recombinant factor VIIa analog NN1731 (V158D/E296V/M298Q-FVIIa) enhances fibrin formation, structure and stability in lipidated hemophilic plasmaThrombosis Research, 2011
- Thrombin signalling and protease-activated receptorsNature, 2000
- Formation and regulation of platelet and fibrin hemostatic plugHuman Pathology, 1987